sacituzumab,patritumab
amgen,gilead,daiichi sankyo
['lung', 'patritumab', 'rux,(-crux),(-trux),(-deruxtecan)', ' sg ', 'rux,(-crux),(-trux)']
patritumab deruxtican - new potential option for her0/1/2 with neg ish. irrespective of her3 or hr expression. &lt;7% with grace 3 or higher ae; 2/60 patients experienced lung toxicity. where to fit/sequence with use of sg (saci)?
#asco23 
Medical Oncologist. Chief of Hem/Onc, PD of hem/onc fellowship, Dr Peter White Endowed Professor, & Associate Professor at The University of Toledo.